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I N T R O D U C T I O N
Peripheral inflammatory injury can lead to increased sensitivity to both noxious and nonnoxious stimuli that persists long after tissue healing. The underlying events involve the induction of short-term activity-dependent changes as well as long-lasting transcriptional or translational changes in dorsal horn neurons. These changes serve to enhance excitatory glutamatergic inputs through N-methyl-D-aspartate (NMDA) and/or Ca 2ϩ -permeable ␣-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor-dependent mechanisms, resulting in central sensitization and wind-up in dorsal horn neurons (reviewed by Sandkuhler 2007; Woolf and Costigan 1999; Woolf and Salter 2000) . The transcriptional and translational mechanisms are similar to those that mediate long-term potentiation in the hippocampus. However, in the spinal cord, the release of substance P (SP) and activation of neurokinin-1 (NK1) receptors play a critical role, at least initially, in the enhancement of excitatory glutamatergic inputs to dorsal horn neurons (Ikeda et al. 2003 (Ikeda et al. , 2006 Ji et al. 2002 Ji et al. , 2003 Randic et al. 1993a,b; Rusin et al. 1992) . Sustained inflammation also enhances excitatory glutamatergic inputs to neurons in the central nucleus of the amygdala, a supraspinal site implicated in the emotional and affective responses to noxious stimulation. However, in contrast, the mechanism involves calcitonin generelated peptide and PKA-mediated phosphorylation of NMDA receptors (Bird et al. 2005; Han et al. 2005) .
It is now understood that persistent inflammatory nociception also affects the function and activity of neurons in the rostral ventromedial medulla (RVM), a critical relay nucleus for the supraspinal modulation of nociception (Millan 2002 ). The RVM is composed of the nucleus raphe magnus and adjacent nucleus reticularis gigantocellularis pars ␣. Neurons in the RVM are a highly heterogeneous population and, although the RVM overlaps with the B3 cell group, serotonergic neurons represent only ϳ25% of RVM neurons (Gao and Mason 2001) . Spinally projecting RVM neurons have long been implicated in the inhibition and, more recently, in the facilitation of nociception (Hammond 1986; Porreca et al. 2002; Urban and Gebhart 1999; Vanegas and Schaible 2004) . Indeed RVM neurons can sustain thermal hyperalgesia or mechanical allodynia after peripheral injury (Burgess et al. 2002; Pacharinsak et al. 2008) .
Conclusions that peripheral inflammatory injury affects the function and activity of RVM neurons were principally based on increases in the potency or efficacy of opioid and glutamatergic agonists and antagonists in the RVM of rats injected with complete Freund's adjuvant (CFA) in the hindpaw (Guan et al. , 2003 Hammond 2000, 2001) . Although changes in opioid receptors were not identified (Sykes et al. 2007) , persistent inflammatory nociception was demonstrated to induce an upregulation in mRNA for several AMPA and NMDA receptor subunits, to increase protein for NR2A and GluR1 subunits and to increase phosphorylation of GluR1 and NR1 subunits (Guan et al. 2003 (Guan et al. , 2004 Miki et al. 2002) . These results suggest that peripheral inflammatory injury enhances glutamatergic synaptic transmission in the RVM, which may contribute to the increase in excitability and activity of specific types of RVM neurons (Kincaid et al. 2006; Miki et al. 2002) . However, direct evidence is still lacking as to whether glutamatergic excitatory synaptic input to RVM neurons is enhanced after peripheral inflammation.
This study tested the hypothesis that persistent inflammatory nociception results in sustained increases in excitatory glutamatergic synaptic inputs to specific populations of RVM neurons. Previous work from this laboratory has identified three different types of spinally projecting nonserotonergic and serotonergic neurons in the RVM (Zhang et al. 2006) . Evoked excitatory postsynaptic currents (eEPSCs) were recorded in spinally projecting RVM neurons using whole cell patch-clamp methods in brain stem slices obtained from rats injected with saline or CFA 3-4 days earlier. The RVM contains SP and high densities of the NK1 receptor (Ljungdahl et al. 1978; Nakaya et al. 1994 ), but few if any NK2 or NK3 receptors (Mileusnic et al. 1999; Saffroy et al. 2003) . Therefore this study further tested whether the facilitation of excitatory glutamatergic inputs observed in CFA-treated rats was dependent on a release of endogenous SP and activation of NK1 receptors on RVM neurons. Last it examined whether exogenously applied SP could mimic the facilitation of excitatory glutamatergic inputs, as well as the contribution of PKC and CaMKII to this effect.
M E T H O D S
These experiments were approved by The University of Iowa Animal Care and Use Committee and were conducted in accordance with the guidelines of the International Association for the Study of Pain and the National Resource Council Guide for the Care and Use of Laboratory Animals.
Developmental issues in recording from RVM neurons
Ten-to 14-day old male Sprague-Dawley rats (Charles River; Portage, IN) were used in this study. Whole cell patch-clamp recordings from RVM neurons are typically restricted to rats Ͻ18 days of age because neuronal viability and visibility are limited at greater ages. Although the use of preweanling rats introduces some developmental concerns, these are not likely to be significant for the present study. With respect to bulbospinal projections, electrical stimulation of the dorsolateral funiculus inhibits C-fiber-evoked responses of dorsal horn neurons after PD10 with reasonably strong inhibition present at PD18 and adult strength of inhibition evident by PD21 (Fitzgerald and Koltzenburg 1986) . Studies of degenerating terminals indicate that bulbospinal projections to the lumbar spinal cord are present at PD4 and exhibit adult-like patterns of degeneration by PD15 (Gilbert and Stelzner 1979) . With respect to AMPA receptors, several laboratories have shown that in the neocortex, hippocampus and cerebellum these receptors mature into the Ca 2ϩ -impermeable GluR2-containing form on or about PD14 (Brill and Huguenard 2008; Ho et al. 2007; Pellegrini-Giampietro et al. 1991 . Finally, with respect to SP, the numbers and affinity of NK1 receptors in brain homogenates from 14-day-old rats do not differ from the adult (Quirion and Dam 1986) . Autoradiographic analysis reveals that the pattern of NK1 binding sites at 14 days of age is virtually identical to that of the adult although higher numbers are present in brain stem nuclei (Quirion and Dam 1986) . However, by 21 days of age, these are also equivalent to the adult. Finally, levels of SP in various regions of the brain at 17 days of age are quite close to those of the adult (Diez-Guerra et al. 1989) .
Retrograde labeling of RVM neurons and induction of hindpaw inflammation
Spinally projecting RVM neurons were retrogradely labeled by placement of a 0.5 mm 3 pledget of sterile Gelfoam, which had been dipped in 0.2% DiI (Molecular Probes, Eugene, OR), beside the dorsal root in juxtaposition to the dorsolateral aspect of the spinal cord (Zhang et al. 2006) . At the completion of surgery, an intraplantar injection of 40 l of saline or complete Freund's adjuvant (CFA) was made in each hindpaw. The immune system of neonatal rats is not well developed in rats at the ages used here (Fitzgerald 1995) . Indeed in preliminary studies, hindpaw inflammation was substantially diminished 2 days after a single injection of CFA and absent by 4 days. Therefore to achieve adequate sustained inflammation, a second injection of 20 l CFA or saline was made 2 days later. Naïve animals were grouped with saline-treated rats for purposes of analysis as there were no differences in data between these two treatment groups.
Slice preparation and whole cell patch recording
Three to 4 days after surgery, the pups were decapitated, and coronal slices of 160-m thickness were cut through the brain stem from the trapezoid body to the inferior olivary nuclei using a vibrating microtome (Leica Microsystems, Bannockburn, IL). Before recording, slices were incubated for Ն30 min in artificial cerebrospinal fluid (ACSF) containing (in mM) 126 NaCl, 2.5 KCl, 25 NaHCO 3 , 1.2 NaH 2 PO 4 , 1.2 MgCl 2 , 2.4 CaCl 2 , and 11 dextrose and equilibrated with 95% O 2 -5% CO 2 . A constant temperature (32-34°C) and flow rate (4 ml.min -1 ) were maintained throughout recording. Whole cell patch-clamp recordings were made from neurons in the RVM using glass recording pipettes of 3-6 M⍀ resistance that contained (in mM) 140 K ϩ methane sulfonate, 10 HEPES, 2 MgCl 2 , 0.6 EGTA, 2 MgATP, and 0.25 Na 2 GTP; pH 7.3, 280 -290 mosM. Biocytin (0.01% wt/vol) was included in the pipette to enable subsequent identification of the neurons. In some experiments, the internal solution also contained 10 M GF109203X or 10 M KN-93 to inhibit PKC or CaMKII, respectively, 0.5% DMSO as the corresponding control for these inhibitors, or 1 mM (5R,10S)-(ϩ)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine hydrogen maleate (MK-801) to block the NMDA receptor.
Recordings were made from retrogradely labeled neurons with an Axopatch 200B amplifier (Axon Instruments, Union City, CA). One neuron was recorded in each slice. An access resistance of Ͻ25 M⍀ was required and monitored for the entire recording. Liquid junction potentials of Ϫ14 mV were uncorrected. A Digidata 1322A board and pCLAMP 9.0 software (Axon Instruments) were used for data acquisition and analysis. The holding potential was maintained at Ϫ60 mV. SP-induced slow inward currents were recorded in gap-free voltageclamp mode with a 50-Hz low-pass filter.
eEPSCs were evoked with a bipolar tungsten stimulation electrode positioned in the reticular formation adjacent to RVM, ϳ500 m lateral to the midline and ϳ500 m dorsal to the pyramid (Fig. 1) . Post hoc analysis of all neurons indicated that the distance between the electrode and the recorded neuron ranged from 0.5 to 0.7 mm. eEPSCs were evoked with constant-current square-wave pulses (0.05-0.45 mA, 0.1 ms, 0.2 Hz) and filtered at 2 kHz. These currents were recorded in the presence of 30 M bicuculline or 100 M picrotoxin and 10 M strychnine in the bath solution. In pilot experiments, this range of stimulus intensities reliably evoked stable EPSCs with few occasions of antidromic excitation. It also enabled us to detect facilitation without encountering a "ceiling effect." Higher stimulus intensities (e.g., Ͼ5 mA) could evoke larger eEPSCs in some neurons but also introduced inconsistency and a higher incidence of antidromic excitation. The eEPSCs were monosynaptic as indicated by the fact that they had a constant latency of Ͻ3 ms at a recording temperature of 33°C and consistently peaked at the same time point. Paired pulse stimulation at 50 ms apart consistently evoked two EPSCs of the same latency that each peaked at a specific time point without failure.
Experimental design
Initial experiments confirmed the presence of functional NK1 receptors on unidentified RVM neurons from naïve rats and established an effective concentration of the antagonist L703,606. Only a single concentration of SP was tested in each neuron. Recordings were conducted in the absence and presence of TTX to establish that the effect of SP was postsynaptic in nature. SP was challenged with 3 M L-703,606 to confirm that the effect was mediated by the NK1 receptor (Cascieri et al. 1992) . The analysis was then extended to spinally projecting RVM neurons in naïve, saline-treated, or CFAtreated rats. A one-way ANOVA and least-squares linear regression were used to confirm the concentration dependence of the effects of SP. Two-way ANOVA in which one factor was SP concentration and the other was TTX treatment was used to compare the effects of 1 and 3 M SP in TTX and untreated slices. A two-way ANOVA was used to compare current produced by 3 M SP in the three different types of neurons in DiI-labeled neurons from naïve rats and CFA-treated rats. Fisher's exact test was used to compare the percentage of serotonergic and nonserotonergic neurons that responded to SP. A 2 test was used to compare the percentage of the different types of neurons that responded to SP. For this and all subsequent analyses, P Ͻ 0.05 was considered significant.
The second set of experiments determined whether persistent inflammatory nociception alters excitatory synaptic inputs to specific types of spinally projecting nonserotonergic RVM neurons. For these experiments, input-output relationships (I-O) were generated for eEPSCs in slices obtained from rats 4 days after intraplantar injection of saline or CFA. Two identical constant-current single square-wave stimuli (S 1 and S 2 , 0.1 ms, 0.2 Hz ranging from 0.05 to 0.45 mA) were delivered 50 ms apart. Each stimulus intensity was repeated five times and the average amplitude of the five eEPSCs evoked by that stimulus intensity (A i ) was calculated as A i S 1 and A i S 2 (the subscript "i" represents the individual stimulus intensity). A i S 1 was used to generate I-O relationships in CFA-and saline-treated rats. The paired pulse ratio (PPR) at each stimulus intensity was calculated as A i S 2 /A i S 1 . A two-way ANOVA was used to compare PPR or eEPSCs between saline-and CFA-treated rats at each stimulus intensity. Comparisons of the slope and intercepts of the I-O relationships were made by analysis of covariance (Graphpad Prism, version 4).
The third set of experiments examined the pharmacological mechanisms responsible for the facilitation of excitatory inputs to RVM neurons in CFA-treated rats. Input-output relationships were generated in slices from CFA-treated rats in the presence of 1 or 3 M L-703,606, a selective NK1 receptor antagonist, or 50 M D-2-amino-5-phosphonopentanoic acid (AP5), an NMDA receptor antagonist. These drugs were added to the ACSF in which the slices were incubated and that was used to perfuse the slices. In other experiments, the intracellular solution contained 1 mM MK-801 or 10 M GF109203X to determine whether postsynaptic NMDA receptors or PKC mediated the facilitation observed in CFA-treated rats.
The fourth set of experiments determined whether brief exogenous administration of SP enhanced excitatory synaptic inputs to spinally projecting, nonserotonergic RVM neurons, in essence mimicking the effects of inflammatory injury. For these experiments, I-O relationships were generated in naïve rats before and 5 min after a 2-min application of 3 M SP. In this case, the eEPSC was normalized to the amplitude of the eEPSC evoked by the 0.4-mA stimulus intensity before application of SP (A 0.4mA S 1 ) and then expressed as a percentage: Relative eEPSC ϭ (A i S 1 /A 0.4mA S 1 )* 100%. The PPR at each stimulus intensity was calculated as A i S 2 /A i S 1 . SP was considered to have facilitated synaptic transmission if the amplitude of the eEPSC was increased by Ͼ20% at a minimum of three consecutive stimulus intensities. A two-way ANOVA in which one factor was treatment and the other factor was stimulus intensity was used to compare EPSCs or PPRs before and after SP application. Newman-Keul's test was used for post hoc comparisons of mean values between the treatment conditions. Slopes of the I-O relationships were compared by t-test.
To determine the time course of facilitation by SP, a fixed-intensity stimulus protocol was used in which EPSCs were evoked repetitively before and over a period of 50 min after application of 3 M SP for 2 min. As a control, this protocol was also conducted in the absence of SP. Two identical constant-current single square-wave stimuli (S 1 and S 2 , 0.1 ms, 0.2 Hz, range: 0.35-0.5 mA among neurons) were delivered 50 ms apart. The average amplitude of the five eEPSCs evoked by that stimulus was calculated as A 1 and A 2. The A 1 was used to evaluate the time course of SP's effect. Baseline values (BL) were determined from the average of 40 A 1 eEPSCs obtained in the 200 s before drug application. Relative eEPSC amplitude was calculated as: (A 1 /BL)*100%. The PPR was calculated as A 2 /A 1 . Comparisons of EPSCs or PPR between control and SP-treated slices were made by two-way repeated-measures ANOVA in which one factor was treatment and the repeated measure was time. Newman-Keul's test was used for post hoc comparisons of mean values between the treatment conditions. SP was considered to have facilitated synaptic transmission if the amplitude of the eEPSC was increased by Ͼ20%. Fisher's exact test was used to compare percentages of neurons that exhibited facilitation among the different treatment groups.
Finally, the potential contribution of the NMDA receptor, PKC or CaMKII to the facilitatory effects of SP was examined by the addition of 50 M AP5 to the perfusate, or the inclusion of 10 M GF109203X (Toullec et al. 1991) or 10 M KN-93 (Sumi et al. 1991) , respectively, in the internal solution of the recording pipette. A fixed stimulus intensity paradigm was used as described in the preceding text. Comparisons of EPSCs in SP-treated slices in the absence or presence of the NMDA receptor antagonist or kinase inhibitor were made by two-way repeated-measures ANOVA in which one factor was treatment and the repeated factor was time. Newman-Keul's test was used for post hoc comparisons of mean values among treatment groups.
Immunohistochemical procedures
The brain stem slice was fixed by immersion for 1 h in 4% paraformaldehyde in 0.1 M phosphate buffer. The slices were washed once for 15 min in 0.1 M phosphate-buffered saline (PBS), incubated for 30 min in 1% (wt/vol) sodium borohydride, rinsed six times for 15 min each in 0.1 M PBS, and then blocked in 0.1 M PBS containing 2% normal goat serum and 0.3% Triton X100 (PBSNT) for 90 min. Sections were then transferred to mouse anti-tryptophan hydroxylase (TrpH, 1:500; Oncogene OP71L; Cambridge, MA) in 0.1 M PBSNT for 40 h at 4°C. After four rinses for 15 min each in 0.1 M PBS, sections were transferred to a mixture of goat anti-mouse IgG conjugated to Cy5 (7.5 g/ml; Jackson ImmunoResearch Laboratories, West Grove, PA) and streptavidin conjugated to Cy2 (3.75 g/ml;
Jackson ImmunoResearch Laboratories) in 0.1 M PBSNT for 90 min. For an ancillary study of NK1 receptor colocalization with TrpH, rabbit anti-NK1 receptor antibody was added to the primary antibody solution (1:5000; Sigma, S-8305, Lot No. 122K4848). The secondary antibody solution contained a mixture of Cy5 goat anti-mouse IgG (7.5 g/ml; Jackson ImmunoResearch Laboratories) and Cy3 goat anti-rabbit IgG (2.25 g/ml; Jackson ImmunoResearch Laboratories). Sections were then rinsed three times in 0.1 M PBS and mounted out of distilled water onto slides. After air drying for 24 h, the sections were coverslipped with Fluoromount G (Electron Microscopy Services; Hatfield, PA). The sections were examined with a BioRad 1024 confocal microscope using sequential, single laser line scanning methods to obtain serial stacks for each fluorophore throughout the entire z axis of the labeled neuron.
A previous study conducted an extensive analysis of the passive membrane and action potential properties of TrpH-immunoreactive type 1-3 neurons and identified criteria (e.g., action potential halfwidth, membrane resistance) that were predictive of the serotonergic nature of a neuron (Zhang et al. 2006) . It determined that 6.7% of type 1 and 8.6% of type 2 neurons that were TrpH-negative exhibited the electrophysiological properties of serotonergic neurons. The percentage for type 3 neurons was 25% of which ϳ80% had capacitances of Յ50 pF. A contributing factor was the small size of these neurons coupled with the extended recording time, which increased dialysis of the intracellular contents (Zhang et al. 2006) . In the present study, none of 21 type 1 neurons (0%), none of 24 type 2 neurons (0%), and only 1 of 21 type 3 neurons (4.7%) for which passive membrane and action potential properties were measured exhibited this discrepancy. The lower percentages most likely reflect a concerted effort to process slices within 2 wk of recording. Therefore the risk of including serotonergic neurons in the population of nonserotonergic neurons was negligible. Neurons were classified as serotonergic if they were immunoreactive for TrpH. Neurons were considered nonserotonergic if they were not immunoreactive for TrpH, but surrounding neurons in the same plane of focus were immunoreactive for TrpH.
Drugs
(Ϯ)bicuculline methiodide, strychnine hemisulfate, picrotoxin, SP acetate salt, 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX, disodium salt), L-703,606 hydrate oxalate salt, GF109203X, AP5, (ϩ)MK-801 hydrogen maleate, and KN-93 were purchased from Sigma (St. Louis, MO). SP, AP5, MK-801, and CNQX disodium salt were dissolved in distilled water, aliquoted, and stored at Ϫ20°C until use. L-703,606 hydrate oxalate salt was dissolved in distilled water and sonicated for ϳ30 min to yield a stock solution of 0.5 mg/ml. All drugs, except the protein kinase inhibitors, were applied by addition to the ACSF and delivered with a BPS8 channel valve control perfusion system (ALA Scientific Instruments; Westbury, NY) controlled by a digital output triggered from pCLAMP. GF109203X and KN-93 were dissolved in dimethyl sulfoxide and added to the internal solution to yield a final drug concentration of 10 M (Sumi et al. 1991; Toullec et al. 1991) . The dimethyl sulfoxide in the internal solution was Ͻ0.5% (vol/vol).
R E S U L T S
Three general types of RVM neurons were identified in the slice preparation from naïve or saline-treated rats based on their spontaneous activity, passive membrane, and action potential properties as previously described (Zhang et al. 2006) . Type 1 neurons fired sporadic action potentials with periods of quiescence that enabled determination of the resting membrane potential. Type 2 neurons were not spontaneously active. Type 3 neurons were spontaneously active but fired repetitively and consistently in a manner that precluded determination of their resting membrane potential. Serotonergic and nonserotonergic neurons within each type could be distinguished electrophysiologically, principally on the basis of action potential amplitude and half-width, and frequency of spontaneous discharge. These same types of neurons could be discerned in CFAtreated rats.
Peripheral inflammation enhances AMPA receptor-mediated excitatory synaptic input to spinally projecting nonserotonergic RVM neurons
Input-output relationships for eEPSCs were generated for nonserotonergic RVM neurons from naïve or saline-or CFAtreated rats to determine if excitatory inputs to spinally projecting neurons in the RVM are enhanced under conditions of persistent inflammatory nociception. All the neurons were DiI-labeled and immunohistochemically identified as nonserotonergic. In saline-treated rats, eEPSCs could be generated in type 1, type 2, and type 3 nonserotonergic neurons. In type 1 or type 3 neurons, eEPSC amplitude increased by four-and fivefold, respectively, as stimulus intensity increased from 0.05 to 0.45 mA (Fig. 2, A and C) . In contrast, type 2 neurons exhibited at most a twofold increase in eEPSC amplitude over the same range of stimulus intensities (Fig. 2B) . Slopes (and 95% confidence limits) of the I-O relationships for type 1, type 2, and type 3 neurons were 422.5 (249.5-595.5), 218.2 (88.0 -348.4), and 581.4 (412.5-750.2) pA/mA, respectively. The slopes of the I-O relationship for type 1 and type 3 neurons were significantly steeper than for type 2 neurons (P Ͻ 0.01). In CFA-treated rats, the I-O relationship for type 1 neurons was shifted up-and leftward to that of saline-treated rats (P Ͼ 0.3 for slope; P Ͻ 0.01 for intercept). The I-O relationship for type 2 neurons in CFA-treated rats was shifted upward in a nonparallel manner (P Ͻ 0.01 for slope). The I-O relationship for type 3 neurons in CFA-treated rats did not differ from that in saline-treated rats (P Ͼ 0.4 for slope, P Ͼ 0.1 for intercept; Fig. 2C ).
To determine whether the enhancement of glutamatergic inputs to spinally projecting RVM neurons involved a presynaptic mechanism, PPRs were determined for eEPSCs in salineand CFA-treated rats. The PPR did not differ between salineand CFA-treated rats at any stimulus intensity (P Ͼ 0.4 all intensities) or among the different cell types at any stimulus intensity (P Ͼ 0.3). For example, at a stimulus intensity of 0.4 mA, the PPRs determined for type 1, type 2, and type 3 neurons in saline-treated rats (n ϭ 3-7) were 1.45 Ϯ 0.12, 1.38 Ϯ 0.07, and 1.22 Ϯ 0.11, respectively. In neurons from CFA-treated rats (n ϭ 6 -8), these values were 1.45 Ϯ 0.03, 1.19 Ϯ 0.09, and 1.43 Ϯ 0.05, respectively. These data indicate that the enhancement is not due to an increased probability of glutamate release, although they do not exclude an increase in the number of release sites (Li and Baccei 2009) .
Contribution of NK1 receptors to the facilitation of excitatory synaptic input to spinally projecting nonserotonergic RVM neurons
Incubation in 3 but not 1 M L-703,606 blocked the facilitation of excitatory synaptic transmission in type 1 neurons in CFA-treated rats. In contrast, incubation in either 1 or 3 M L-703,606 completely prevented the facilitation of eEPSCs in type 2 neurons in CFA-treated rats (Fig. 2, A and B) . Incuba-tion in 3 M L-703,606 did not shift the I-O relationship for type 1 or type 2 neurons in saline-treated rats (Fig. 3, A and B) . The sole exception was at 0.45 mA in type 1 neurons. These data suggest that in the absence of inflammatory nociception, NK1 receptors and endogenously released SP are not involved in modulation of eEPSCs in type 1 or type 2 RVM neurons. However, under conditions of persistent inflammatory nociception, there is a release of SP onto these neurons that functions to facilitate responses to endogenously released glutamate. Figure 4 (top) illustrates that 10 M CNQX nearly completely antagonized eEPSCs in a type 2 neuron from a CFA-treated rat. These data indicate that fast eEPSCs in CFA-treated rats are still mediated by AMPA receptors and that the facilitation by SP is a modulatory effect.
A different finding was made with respect to type 3 neurons. Incubation in 1 M L-703,606 did not affect the I-O relationship in type 3 neurons from CFA-treated rats (Fig. 2C) . Although 3 M L-703,606 decreased the amplitude of eEPSCs in type 3 neurons from CFA-treated rats, it also produced an equivalent decrease in the amplitude of the eEPSCs in type 3 neurons from saline-treated rats (Fig. 3C) . Moreover, L-703,606 decreased the frequency of spontaneous action potentials in type 3 neurons from 6.1 Ϯ 0.9 (n ϭ 10) to 2.8 Ϯ 0.3 Hz (n ϭ 7; P Ͻ 0.05) in normal rats but did not alter the regularity of their discharge (CV ISI : 0.13 Ϯ 0.03 vs. 0.16 Ϯ 0.02). Figure 4 (bottom) illustrates that eEPSCs from a type 3 neuron in a saline-treated rat were virtually abolished by 10 M CNQX, again indicating that the fast EPSCs are mediated by AMPA receptors. Thus unlike type 1 and type 2 neurons, type 3 neurons normally receive a SP input mediated by NK1 receptors that functions to facilitate glutamatergic synaptic transmission. Furthermore, this input is unchanged under conditions of persistent inflammatory nociception.
Role of PKC in the facilitation of excitatory synaptic input to spinally projecting nonserotonergic RVM neurons
The NK1 receptor is well established to couple to G q/11 and to activate PKC. A limited series of experiments was conducted to determine whether facilitation of excitatory inputs in CFA-treated rats involved PKC. Figure 2 illustrates that when 10 M GF109203X was present in the internal solution, facilitation was not obtained in type 1 and nearly abolished in type 2 neurons. In type 3 neurons from CFA-treated rats, inclusion of GF109203X did not appear to alter the I-O curve, although considerable variability in the amplitude of the currents evoked among the four neurons hampered meaningful statistical analysis.
Contribution of NMDA receptors to the facilitation of excitatory synaptic input to spinally projecting nonserotonergic RVM neurons in CFA-treated rats
Incubation in 50 M AP5, an NMDA receptor antagonist, completely prevented the facilitation of eEPSCs in type 1 and type 2 neurons from CFA-treated rats. However, inclusion of the noncompetitive NMDA receptor antagonist MK-801 in the internal solution did not prevent the facilitation of eEPSCs in type 1 or type 2 neurons from CFA-treated rats (Fig. 3, A and   FIG. 2 . Persistent inflammatory nociception potentiates evoked excitatory postsynaptic currents (eEPSCs) in specific populations of spinally projecting nonserotonergic rostral ventromedial medulla (RVM) neurons: role of NK1 receptors. Input-output (I-O) relationships generated for spinally projecting, nonserotonergic type 1 (A), type 2 (B), and type 3 (C) neurons from saline-and complete Freund's adjuvant (CFA)-treated rats. Bath application of 1 M L-703,606 completely abolished the facilitation of eEPSCs in type 2 neurons, whereas a higher concentration was required to antagonize the facilitation in type 1 neurons in CFA-treated rats. Inclusion of 10 M GF109203X in the internal solution also abolished the facilitation of eEPSCs in type 1 and type 2 neurons. Right: traces of EPSCs evoked by stimulation with 0.1, 0.2, 0.3, and 0.4 mA in a representative neuron from the CFA and saline treatment groups. Calibration bars are the same for all panels. *P Ͻ 0.05, **P Ͻ 0.01 compared with saline-treated group; †P Ͻ 0.05, ‡P Ͻ 0.01 compared with CFA-treated group. Data are the means Ϯ SE.
B).
Neither bath application of AP5 nor inclusion of MK-801 in the internal solution altered the I-O relationship in type 3 neurons from CFA-treated rats (Fig. 3, A-C) . These data implicate presynaptic but not postsynaptic NMDA receptors in the facilitation of AMPA receptor-mediated synaptic inputs to specific classes of spinally projecting, nonserotonergic neurons that occurs following inflammatory injury.
Exogenous SP enhances AMPA receptor mediated excitatory synaptic transmission in nonserotonergic RVM neurons from naïve animals
Input-output relationships were generated for eEPSCs in nine SP-responsive nonserotonergic neurons (of which 7 were DiI-labeled) in naïve rats before and 5 min after a 2-min application of 3 M SP (Fig. 5, A-C) . The I-O relationships shifted to the left and upward in five neurons (2 type 1, 2 type 2, and 1 type 3; Fig. 5B , P Ͻ 0.01) and were unchanged in the other four neurons (3 type 2, 1 type 3; Fig. 5C , P Ͼ 0.3). As there was no clear difference among neuron types, they were pooled for the purpose of illustration. To determine the time course over which facilitation occurred, eEPSCs evoked by a fixed-intensity stimulus were recorded from eight SP-responsive nonserotonergic neurons (3 type 1, 2 type 2; 3 type 3; 4 were DiI-labeled ) over a period of 50 -60 min. As there was no difference in the time course of facilitation among the different types of neurons or by DiI status, they were pooled for further analysis. Application of 3 M SP for 2 min FIG. 3. Persistent inflammatory nociception potentiates eEPSCs in specific populations of spinally projecting nonserotonergic RVM neurons: role of N-methyl-D-aspartate (NMDA) receptors. I-O relationships generated for spinally projecting, nonserotonergic type 1 (A), type 2 (B), and type 3 (C) neurons from saline-and CFA-treated rats. Bath application of 50 M D-2-amino-5-phosphonopentanoic acid (AP5) abolished the facilitation of eEPSCs in type 1 and type 2 neurons but did not affect the amplitude of eEPSCs in type 3 neurons from CFA-treated rats. Inclusion of 1 mM MK-801 in the internal solution did not prevent the facilitation of eEPSCs in type 1 or type 2 neurons and did not alter the I-O curve in type 3 neurons from CFA-treated rats. In saline-treated rats, bath application of 3 M L-703,606 did not alter the I-O relationships for type 1 or 2 neurons but uniformly decreased the amplitude of eEPSCs in type 3 neurons. Right: traces of EPSCs evoked by stimulation with 0.1, 0.2, 0.3, and 0.4 mA in a representative neuron from CFA-treated rats in the presence of intracellular MK-801 or AP5 in the perfusate. Calibration bars are the same for all panels. *P Ͻ 0.05, **P Ͻ 0.01 compared with salinetreated group; †P Ͻ 0.05, ‡P Ͻ 0.01 compared with CFA-treated group. Data are the means Ϯ SE. FIG. 4 . Top: traces of eEPSCs evoked by different strength stimuli recorded in a type 2 neuron from a CFA-treated rat. Note that 10 M 6-cyano-7-nitroquinoxalene-2,3-dione (CNQX) nearly abolishes the eEPSC evoked by the highest stimulus intensity tested (0.4 mA). Bottom: eEPSCs evoked by different strength stimuli recorded in a type 3 neuron from a saline-treated rat. Again, 10 M CNQX nearly abolishes the eEPSC evoked by the highest stimulus intensity tested (0.4 mA). Traces in both panels are the average of 5 sweeps. The stimulus artifact has been truncated. Scale bars are 100 pA and 10 ms. These data indicate that the eEPSCs in CFA-and saline-treated rats are nearly exclusively mediated by AMPA receptors and suggest that SP does not mediate fast excitatory synaptic transmission in either condition.
increased the amplitude of the eEPSCs in six of the eight neurons for ϳ25 min (Fig. 6A) . The PPR did not change in SP-treated slices (P Ͼ 0.4; Fig. 6B ). No facilitation of eEPSCs was observed in six nonserotonergic neurons recorded in the absence of SP (2 type 1, 4 type 2; Fig. 6A ).
Previous reports have implicated phosphorylation of Ser Facilitation of eEPSCs by SP was also observed when the internal solution contained 0.5% DMSO (F, n ϭ 7). However, SP did not facilitate eEPSCs when the protein kinase C inhibitor GF109203X was present in the recording pipette (E, n ϭ 9). SP retained its ability to facilitate eEPSCs in the presence of 50 M AP5 (‚, n ϭ 10). The amplitude of eEPSCs evoked by a fixed stimulus intensity in the absence of SP was stable throughout the 50-min recording period ᮀ, n ϭ 6). All neurons responded to SP with an inward current. Inset: an expanded view of the 1st 7 min of recording. Note that GF109203X by itself did not alter eEPSCs in the 3.5 min prior to application of SP, during the 2-min application of SP, or in the 1.5 min thereafter, indicating that the PKC inhibitor was without effect on its own. Data are expressed as a percentage of the amplitude of the eEPSC evoked by the stimulus intensity during the baseline recording period. Symbols are the means Ϯ SE. *P Ͻ 0.05 compared with control at the corresponding time point. B: paired-pulse ratio for eEPSCs in the 8 SPresponsive neurons did not change after brief application of 3 M SP during the 50-min recording period. Data are the means Ϯ SE. Data were extracted at 1.7-min intervals for purposes of clarity. Inset: the EPSCs evoked by paired pulse stimuli delivered 50 ms apart to a type 1 neurons before (-) and 25 min after (---) a 2-min application of 3 M SP. Traces are the average of 5 sweeps. Scale bars are 200 pA and 10 ms.
nonserotonergic neurons recorded with internal solution containing 0.5% DMSO (1 type 1, 5 type 2, 1 type 3) exhibited enhanced eEPSCs following brief application of SP (P Ͻ 0.01, Fisher exact test, compared with GF109203X group, Fig. 6A) . Similarly, six of eight SP-responsive nonserotonergic neurons recorded with normal internal solution (3 type 1, 2 type 2; 3 type 3) exhibited enhanced eEPSCs after brief application of SP. GF109203X by itself had no effect as determined by comparing eEPSCs in this treatment group in the 3.5 min preceding SP application and the 2 min during SP application to corresponding time points in the DMSO control group, as well as either treatment group in which the pipette contained the normal internal solution (Fig. 6A, inset) .
When the CaMKII inhibitor KN-93 (10 M) was present in the internal solution, the proportion of neurons in which brief application of SP caused facilitation (3 of 6) was similar to the proportion in which facilitation occurred when the recording pipette contained 0.5% DMSO (5 of 7; P Ͼ 0.5). In addition, the magnitude of facilitation obtained in those three neurons did not differ from that obtained in the absence of the CaMKII inhibitor. Thus eEPSC amplitude determined 10, 20, 30, and 35 min after application of SP was 163.6 Ϯ 13.9, 208.0 Ϯ 48.0, 207.5 Ϯ 48.8, and 167.6 Ϯ 47.9% (n ϭ 3), respectively.
When 50 M AP5 was present in the perfusate, SP retained its ability to facilitate eEPSCs. Thus 6 of 10 neurons (1 type 1, 4 type 2, 1 type 3) exhibited enhanced eEPSCs after brief application of SP (Fig. 6A) . The magnitude of facilitation did not differ from that determined in the absence of AP5 (P Ͼ 0.2).
Functional NK1 receptors are expressed by spinally projecting nonserotonergic RVM neurons
An initial analysis of the effects of SP was made using 45 neurons in the RVM of naïve rats that did not undergo retrograde labeling or immunohistochemical analysis. These neurons had electrophysiological characteristics of nonserotonergic neurons (Zhang et al. 2006) . A neuron was considered responsive if application of SP induced an inward current Ն8 pA within 30 -50 s of application that peaked at 60 -80 s and desensitized thereafter. Of the 45 neurons, 28 (62%) responded to bath application of SP with a rapidly desensitizing inward current (Fig. 7A) . The proportion of RVM neurons that responded to 0.3, 1, or 3 M SP did not differ among type 1 (68%; 11/16), type 2 (58%; 10/17), and type 3 (58%; 7/12) neurons (P Ͼ 0.7). Therefore these neurons were pooled to generate a concentration-response curve. Application of 0.3, 1, or 3 M SP produced a concentration-dependent inward current with mean amplitudes of 9.3 Ϯ 2.1 pA (4 of 7 neurons), 23.0 Ϯ 3.4 pA (4 of 6 neurons), and 36.8 Ϯ 4.7 pA (20 of 32 neurons), respectively. To establish that the inward current produced by SP was the result of a direct postsynaptic effect, 11 neurons were recorded in the presence of 1 M TTX (Fig.  7A ). Of these 11 neurons, 9 responded to 1 or 3 M SP. The mean inward currents produced by 1 and 3 M SP were 14.2 Ϯ 2.6 (n ϭ 6) and 50 Ϯ 5.8 pA (n ϭ 3), respectively, and were not statistically different from those recorded in the absence of TTX (2-way ANOVA, P Ͼ 0.7). To verify that the inward current was mediated by NK1 receptors, slices were incubated in 3 M L-703,606. Incubation for Ն5 min (usually Ͼ30 min) in L-703,606 completely abolished the effect of 1 M SP in all six neurons examined (Fig. 7B) . Shorter periods of exposure to the antagonist were not as effective.
A subsequent experiment ascertained the distribution of functional NK1 receptors on spinally projecting RVM neurons in naïve and CFA-treated animals. Of the 31 neurons from naïve rats that were retrogradely labeled with DiI from the spinal cord and immunohistochemically identified to be nonserotonergic, 21 (68%) were responsive to application of either 1 or 3 M SP. The amplitudes of the inward current produced by 1 and 3 M SP were 26.2 Ϯ 4.7 pA (5 of 7 neurons) and 39.7 Ϯ 4.2 pA (16 of 24 neurons), respectively. The proportion of type 1, type 2, and type 3 neurons responsive to 3 M SP was 50% (4 of 8 neurons), 78% (7 of 9 neurons), and 71% (5 of 7 neurons), respectively (P Ͼ 0.4). The mean amplitude of inward currents produced by 3 M SP in type 1, type 2, and type 3 neurons from naïve rats was 38.3 Ϯ 6.4 (n ϭ 4), 36.3 Ϯ 5.4 (n ϭ 7), and 45.6 Ϯ 10.7 (n ϭ 5) pA, respectively. In CFA-treated rats, 3 M SP evoked significantly smaller inward currents of 19.8 Ϯ 4.1 (n ϭ 4), 21.0 Ϯ 3.5 (n ϭ 7), and 15.6 Ϯ 1.7 (n ϭ 5) pA in type 1, type 2, and type 3 neurons, respectively (P Ͻ 0.05 for each cell type).
Functional NK1 receptors are not expressed by spinally projecting serotonergic RVM neurons
Bath application of 1 or 3 M SP did not produce an inward current in any of the nine immunohistochemically identified, spinally projecting serotonergic neurons to which it was applied. By comparison, these concentrations produced an inward current in 21 of 31 spinally projecting nonserotonergic neurons FIG. 7. Effects of SP on RVM neurons. A: representative recording from a nonserotonergic RVM neuron illustrating the rapidly desensitizing, inward current produced by 1 M SP and its persistence in the presence of 1 M tetrodotoxin. B: pretreatment with 3 M L-703,606, an NK1 receptor antagonist, prevented the effect of SP in another nonserotonergic RVM neuron. C: representative recording from a spinally projecting, serotonergic RVM neuron illustrating that application of 1 M SP was without effect.
(P Ͻ 0.05, Fisher exact test). Figure 7C illustrates the lack of effect of 1 M SP on an immunohistochemically identified, spinally projecting serotonergic RVM neuron. Given that sampling bias is always present in electrophysiological studies, additional confirmation of the absence of NK1 receptors on serotonergic RVM neurons was obtained by immunohistochemical analysis. Of the 50 TrpH-immunoreactive profiles counted in randomly placed grids in the RVM of eight slices from two 14-day-old pups, none colocalized the NK1 receptor. Figure 8 provides examples of immunohistochemical staining for the NK1 receptor and TrpH in the RVM in the slice preparation. The lack of effect of SP and absence of NK1 receptors on spinally projecting serotonergic neurons excludes an NK1-dependent postsynaptic mechanism for facilitation of excitatory inputs to this population of RVM neurons.
D I S C U S S I O N

Persistent inflammatory nociception causes long-term facilitation of glutamatergic inputs to spinally projecting nonserotonergic RVM neurons
The present study is the first direct evidence that persistent inflammatory nociception leads to a sustained facilitation of fast excitatory glutamatergic inputs to nonserotonergic, spinally projecting RVM neurons. Further, it demonstrates that the facilitation is not a generic phenomenon but restricted to specific populations of nonserotonergic RVM neurons. Finally, it indicates that endogenously released SP, PKC, and presynaptic NMDA receptors play a critical role in the facilitation and that exogenous application of SP can mimic this effect in a PKC dependent manner.
Mechanisms of facilitation in type 1 and type 2 neurons: role of SP and the NK1 receptor
The inability of L-703,606 to diminish the amplitude of eEPSCs in type 1 or type 2 neurons in saline-treated rats suggests that in the absence of inflammatory injury, SP is not released in sufficient amounts to modulate glutamatergic synaptic transmission to these neurons. However, L-703,606 prevented the facilitation of excitatory glutamatergic inputs to type 1 and type 2 neurons in CFA-treated rats, which suggests that SP is released in the RVM under conditions of persistent inflammatory nociception. Although an increase in NK1 receptor number or affinity could be proposed, SP produced smaller, not larger inward currents in RVM neurons from CFA-treated rats. Such a finding is not consistent with an increase in receptor affinity or number but is consistent with an internalization or downregulation of the NK1 receptor in the face of enhanced or sustained release of SP Marvizon et al. 1997) . Importantly, application of a low concentration of the AMPA receptor antagonist CNQX nearly completely abolished the EPSCs evoked by a high stimulus intensity that caused a threefold increase in eEPSC. This finding indicates that in CFA-treated rats, the eEPSCs remain AMPA receptor mediated and that the function of increased SP release is to modulate the actions of glutamate but not mediate fast excitatory synaptic transmission itself.
Functional NK1 receptors are expressed by nonserotonergic spinally projecting RVM neurons
The present results document that functional NK1 receptors are expressed by a majority of nonserotonergic neurons in the RVM that project to the spinal cord. Although previous extracellular unit recordings determined that SP excites a subset of RVM neurons (Budai et al. 2007; Pomeroy and Behbehani 1980) , these studies provided little information as to their projections and neurotransmitter content. A recent study in adult rat also determined that a majority of spinally projecting neurons express NK1 receptor immunoreactivity but did not determine the neurotransmitter content of those neurons (Pinto et al. 2008) . Neither whole cell recordings nor an immunohistochemical analysis identified NK1 receptors on serotonergic RVM neurons. In the rodent dorsal raphe nucleus, which contains a high-density of serotonergic neurons, Commons and Valentino (2002) concluded that only 4% of NK1-like immunoreactive processes colocalized TrpH-like immunoreactivity. However, Lacoste et al. (2006) determined that as many as 37% of TrpH-positive processes were also immunoreactive for the NK1 receptor. The antibody used in this study recognizes only the long isoform of the NK1 receptor. However, it is unlikely that serotonergic neurons preferentially express the C-terminally truncated isoform of the NK1 receptor (Caberlotto et al. 2003; Carletti et al. 2005 ) because SP did not produce inward currents in these neurons.
Exogenous SP facilitates excitatory glutamatergic inputs to nonserotonergic RVM neurons
Brief exposure of the slice to SP (2 min) resulted in a prolonged facilitation of eEPSCs in nonserotonergic RVM neurons that lasted ϳ30 min. Brief exposure to SP also produces a long-term potentiation of glutamatergic inputs to dorsal FIG. 8 . Two examples of NK1-like immunoreactivity and TrpH-like immunoreactivity in the RVM in slices prepared from 14-day-old rats. Each image is a single stack of 1 m thickness. 2, NK1 receptor-like immunoreactive neurons that were not immunoreactive for TrpH. Many TrpH-like immunoreactive neurons that do not colocalize NK1-like immunoreactivity are also present.
horn neurons (Dougherty et al. 1993; . The NK1 receptor is coupled to G q/11 and activates PLC leading to formation of IP 3 and diacylglycerol and activation of PKC (Khawaja and Rogers 1996; Krause et al. 1993; Mantyh et al. 1984) . Both PKC and CaMKII are implicated in the facilitatory effects of SP on glutamatergic transmission in the spinal cord (Ikeda et al. 2003 (Ikeda et al. , 2006 Rusin et al. 1993b ). The present results provide strong evidence for a role of PKC in the actions of SP in the RVM as well. Indeed antagonism of PKC not only prevented the facilitatory effects of exogenously applied SP, it also prevented the facilitation of eEPSCs observed in CFA-treated rats consistent with the proposal that this effect is mediated by endogenously released SP.
The role of CaMKII is less clear. Inclusion of KN-93 in the recording pipette did not prevent facilitation and the percentage of neurons exhibiting facilitation and the magnitude of facilitation was the same as in its absence. Levels of mRNA and protein for CaMKII isoforms are very low in brain stem and even lower in rats of the age used here (Brocke et al. 1995; Burgin et al. 1990; Erondu and Kennedy 1985; Sahyoun et al. 1985; Yasuda et al. 2003) . Thus the negative result with KN-93 must be interpreted cautiously because it could simply reflect insufficient levels of CaMKII (Yasuda et al. 2003) . The role of PKA was not examined because activation of cAMP and PKA by SP acting at NK1 receptors is not a consistent finding (Krause et al. 1993 ; but see Rusin et al. 1992 ).
Mechanisms of facilitation in type 1 and type 2 neurons:
role of the NMDA receptor SP can potentiate inward currents produced by NMDA in dorsal horn neurons via the NK1 receptor and PLC-and PKC-dependent mechanisms (Cumberbatch et al. 1995; Ikeda et al. 2003; Rusin et al. 1993a) . Moreover, nearly all RVM neurons that are immunoreactive for the NK1 receptor colocalize the NR1 subunit of the NMDA receptor (Budai et al. 2007 ). Levels of mRNA for NR1, NR2A, and NR2B subunits of the NMDA receptor increase in the RVM after CFA treatment (Miki et al. 2002) . Thus facilitation of eEPSCs in CFAtreated rats could arise from the ability of synaptically released SP to facilitate the effects of glutamate on postsynaptic NMDA receptors and in this manner activate kinases such as PKC and CaMKII. These kinases can in turn phosphorylate the AMPA receptor and amplify its activity as well as facilitate its translocation to the synapse (Derkach et al. 2007; Soderling and Derkach 2000) . Indeed, phosphorylation of Ser 831 residues in AMPA receptors occurs in the RVM after inflammatory injury (Guan et al. 2004) . In this study, amplification occurs in the absence of an increase in the release of glutamate itself as demonstrated by the absence of any change in the PPR of eEPSCs in CFA-treated rats.
At the holding potential in this study (Ϫ60 mV; Ϫ74 mV corrected), postsynaptic NMDA receptors should not contribute to the fast EPSCs recorded in RVM neurons (Keller et al. 1991) . Nonetheless, the NMDA receptor antagonist AP5 also completely antagonized the facilitation of eEPSCs in type 1 and type 2 neurons from CFA-treated rats. Inclusion of MK-801 in the internal solution did not prevent the facilitation of eEPSCs in type 1 or type 2 neurons from CFA-treated rats. Moreover, addition of AP5 to the perfusate did not block the ability of exogenously applied SP to facilitate eEPSCs in RVM neurons from naïve rats. Thus under the recording conditions of this study, postsynaptic NMDA receptors do not appear to play a critical role.
Studies in dorsal horn neurons have established that activation of presynaptic NMDA receptors on the central terminals of peptidergic primary afferents causes an increased release of SP after dorsal root stimulation or administration of capsaicin (Afrah et al. 2001; Liu et al. 1997; Malcangio et al. 1998; Marvizon et al. 1997 ; but see Nazarian et al. 2008) . A similar mechanism may be invoked in the RVM in which synaptically released glutamate acts at presynaptic NMDA receptors on SP-containing afferents to RVM neurons. This idea is consistent with the ability of either AP5 or L-703,606 to completely reverse the enhancement of eEPSCs in type 1 and type 2 neurons in CFA-treated rats. Type 1 and type 2 nonserotonergic spinally projecting RVM neurons receive inputs from SP-containing neurons. In the absence of inflammation, these inputs are quiescent because administration of L-703,606 did not diminish eEPSCs in saline-treated rats. We therefore speculate that persistent inflammatory nociception leads to an upregulation of NMDA receptors on the terminals of SPcontaining afferents to RVM neurons, providing a means by which synaptically-released glutamate can cause a concomitant release of SP and activation of postsynaptic NK1 receptors. This idea has support in the literature with the finding that NMDA receptors are upregulated on SP-containing afferents in the dorsal horn under conditions of opioid tolerance (Zeng et al. 2006) .
Persistent inflammatory nociception does not facilitate glutamatergic inputs to type 3 RVM neurons
L-703,606 decreased both the spontaneous activity of nonserotonergic spinally projecting type 3 neurons and the amplitude of glutamatergic eEPSCs in saline-treated rats. These data suggest that nonserotonergic spinally projecting type 3 RVM neurons normally receive a tonically active input from SPcontaining neurons. As a result, AMPA receptors in these neurons may already be highly phosphorylated and no further enhancement may occur. It is also possible that persistent inflammatory nociception does not lead to an upregulation of NMDA receptors on SP-containing afferents to these neurons. The ability of exogenously administered SP to facilitate excitatory inputs to type 3 neurons is not inconsistent with the absence of facilitation in CFA-treated rats when one considers that physiological concentrations of SP may not fully saturate all available NK1 receptors.
Functional properties of RVM neurons
Collectively, these data permit some speculation about the function of the three different types of spinally projecting nonserotonergic RVM neurons. Type 3 neurons fire regularly and at high frequency in the slice preparation. They are tonically driven by SP. Their responsiveness to excitatory glutamatergic inputs is not altered after inflammatory injury. In the absence of inflammatory injury, microinjection of NK1 receptor antagonists in the RVM does not alter either thermal or mechanical thresholds to noxious stimulation (Pacharinsak et al. 2008 ) (M. Hamity, S. White, and D. L. Hammond, unpublished observations). Thus, it is unlikely that this class of neuron is involved in the modulation of persistent inflammatory nociception in the spinal cord dorsal horn (Kincaid et al. 2006; Xu et al. 2007 ; but see Miki et al. 2002) . As such, they may correspond to a type of neutral cell using the classification scheme of Fields. Neutral cells discharge regularly and do not respond to acute noxious stimulation or alter their activity on administration of antinociceptive agents (Fields 2004; Mason 1999 ). It will be of interest to determine whether these neurons are unresponsive to opioid agonists.
Type 2 nonserotonergic neurons do not discharge spontaneously in slices from either saline or CFA-treated rats. However, the responsiveness of these neurons to excitatory glutamatergic inputs is dramatically increased after inflammatory injury, an effect that is prevented by a low concentration of L-703,606. Microinjection of NK1 receptor antagonists in the RVM alleviates thermal hyperalgesia and mechanical allodynia produced by intradermal capsaicin (Pacharinsak et al. 2008) or intraplantar injection of CFA in the hindpaw (Hamity et al. 2008) . Thus a subset of type 2 nonserotonergic neurons are likely to function as pain facilitatory neurons. These neurons may correspond to ON cells because application of SP excites only this population of RVM neuron and facilitates excitatory responses to NMDA (Budai et al. 2007 ). Moreover, ON cells fire sporadically at very low frequencies or lack spontaneous activity in vivo.
Type 1 neurons discharge sporadically in slices from either saline-or CFA-treated rats. The responsiveness of these neurons to excitatory glutamatergic inputs is also increased under conditions of persistent inflammatory nociception. Complete antagonism of the enhancement of I-O relationships in these neurons required a slightly higher concentration of L-703,606. Some of these neurons may also correspond to ON cells.
Conclusions
The present findings provide the first evidence that specific populations of nonserotonergic neurons in the RVM that project to the spinal cord are affected by persistent inflammatory nociception in a manner that selectively increases the efficacy of excitatory glutamatergic inputs to these neurons. The mechanism is dependent on both NK1 and NMDA receptors and involves activation of PKC. We propose that persistent inflammatory nociception leads to an increased release of endogenous SP that acts at NK1 receptors to activate PKC, as is common for this G q -coupled receptor with a concomitant phosphorylation of AMPA receptors. We further speculate that persistent inflammatory nociception may cause an upregulation of NMDA receptors on SP-containing afferents to the RVM providing a means by which synaptically released glutamate can promote the release of SP. These mechanisms are likely to function in concert and provide a basis for sustained thermal hyperalgesia and mechanical allodynia even as peripheral inflammation wanes after injury. Finally, although this study focused on facilitation in RVM neurons that project to the spinal cord, the occurrence of facilitation in RVM neurons that project to other supraspinal nuclei implicated in nociception (e.g., the A7 nucleus of the dorsolateral pontine tegmentum) should not be excluded.
